Pipeline

AZAD continually invests into further development and expansion of its FP portfolios. Development and validation of FPs is undertaken at EU-based contract manufacturers facilities under the direction of Azad`s pharmaceutical and regulatory specialists to produce CTD-format Dossiers, which are then out-licensed for customers to submit marketing authorization applications worldwide (ex-USA).

Finished Products

Product	Therapeutic Indication	Status
Dorzolamide + Timolol Preservative (BAK)-free, 10.0 mL Eye Drops solution in 10 mL Preservative-free bottle for 2 months in-use, 20 mg/mL + 5 mg/mL, eye drops solution in 10mL (15.0 mL bottle for 3 months in-use under consideration)	Treatment of Glaucoma	Under development
Brinzolamide+ Timolol Preservative (BAK)-free, Eye Drop Suspension in 10.0 ml Preservative-free bottle for 2 months in-use, 10 mg/mL Brinzolamide+ 5 mg/mL Timolol (15.0 ml bottle 3 months in-use under consideration)	Treatment of Glaucoma	Under development
Brinzolamide Preservative (BAK)-free, 10.0 mL Eye Drops suspension in 10 mL bottle, for 2 months in-use, 10 mg/mL Brinzolamide (15.0 mL bottle 3 months in-use under consideration)	Treatment of Glaucoma	Under development
Bimatoprost + Timolol Preservative (BAK)-free, 6.5 ml Eye drops microemulsion in 10 mL bottle for 3 months in-use, 100 mcg/mL Bimatoprost+ 5 mg/mL Timolol	Treatment of Glaucoma	Under development
Bimatoprost Preservative (BAK)-free, 6.5 ml Eye Drops microemulsion in 10 ml bottle for 3 months in-use, 100 mcg/ml Bimatoprost	Treatment of Glaucoma	Under development